News

PARIS, France, and MONTREAL, Canada, 04 May 2020 — Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian drug discovery and research commercialization center, and Université de Montréal, today announced they entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology program.
Under the leadership of […]

 
The new issue of BIOTECanada’s Insights magazine is now available. IRICoR is proud to have collaborated on this edition. Find an article in Q&A format with selected IRICoR partners, highlighting the importance of collaboration in research and life sciences, pillar of the IRICoR business model and key to its success.
 
To read the full article, click here.
To […]

Montréal, March 19 2020 – Given the exceptional circumstances currently surrounding the COVID-19 pandemic and in compliance with the policies implemented by our governments, which have declared a state of health emergency, IRICoR management has decided to introduce certain temporary measures in order to reduce contact and the risk of transmission. To do so, all IRICoR staff members have been […]

IRICoR is proud to welcome Ms. Clara Scattolin to its team, as Junior Project Manager.
Ms. Scattolin will be in charge of coordinating all ad hoc projects, assisting in the drafting of administrative reports related to reporting to funding agencies, and helping to set up events related to entrepreneurial initiatives.
Ms. Scattolin is excited about beginning her professional career at IRICoR. Along […]

 
Dr. Nadine Beauger, CEO at IRICoR, participated in an NFB (National Film Board of Canada) project, Women scientists.
The idea is to present the diversity of women scientists across Canada, in short video capsules.
The purpose of these capsules is to inspire and encourage young people (and especially young women) to pursue their careers in science.
 
To view the […]

IRICoR and Oncopole are very proud to announce the recipients of their 3rd edition of Scholarship Competition – Entrepreneurship in Oncology (CEO).
This initiative offers the next generation of scientists an opportunity to take part in the Life Sciences Entrepreneurship Development Program initiated by a partnership between Montréal InVivo, the 

Montreal, February 10, 2020 – IRICoR is delighted to have taken part in the third edition of the “Behind the scenes of cancer research” event. The evening, hosted by scientific journalist Yannick Villedieu, was opened by a panel with Dr. Nadine Beauger, Chief Executive Officer at IRICoR and Dr. Sébastien Carréno, principal investigator at IRIC.
This panel was followed by an […]

A partnership between IRICoR and Ovarian Cancer Canada
 
For the past 10 years, IRICoR has targeted the best academia-based projects in order to translate them into innovative therapies that will benefit patients. So far, IRICoR has made close to 80 financings in high-quality projects, established more than 20 strategic partnerships with key players, both locally and internationally, towards initiation of 7 […]

Montréal and Martinsried/Munich, 30 January 2020 – IRICoR, a pan-Canadian drug discovery research commercialization centre and the Université de Montréal (UdeM) announce today that they have entered into a research collaboration on novel cancer antigens for highly specific immunotherapies with Medigene, a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies.
UdeM’s research team, led by […]

Photo credit : @mirrorimagemedia, NFB project #MySTEMjob
IRICoR is pleased to announce the appointment of its Chief Executive Officer, Dr. Nadine Beauger, to Immune Biosolutions Board of Directors.
Immune Biosolutions is an early-stage biopharmaceutical company focused on the discovery, engineering and development of humanized chicken antibodies that target intractable membrane proteins with a validated therapeutic potential. Immune Biosolutions’ current pipeline of therapeutic […]